Genprex Inc. (GNPX) Short-Term Debt to Equity

The linear price action on the Genprex, Inc. (GNPX) chart reflects the financial standing of a company whose risks are tied to a lack of commercial products and potential early-stage test failures, with the indicator standing at 0.00. The business focuses on developing gene restoration methods to combat diabetes and tumors. Operations rely on ONCOPREX technology and partnerships with US scientific centers.

This indicator compares liabilities with a maturity of up to one year against equity to determine the company's dependence on rapid refinancing. For Genprex, Inc. (GNPX), which invests in nanoparticles for gene therapy, the current ratio of short-term liabilities to equity demonstrates a balance between operational liquidity and the risk of asset dilution during costly clinical trials.